Early Noninvasive Ventilation May Not Be Better for Patients With Acute Respiratory Failure
the ONA take:
Among immunocompromised patients admitted to intensive care units (ICUs) with hypoxemic acute respiratory failure, early noninvasive ventilation did not reduce 28-day mortality compared with oxygen therapy alone, according to a new study published online ahead of print in JAMA.
Although noninvasive ventilation has been recommended to decrease mortality among immunocompromised patients with hypoxemic acute respiratory failure, its effectiveness has remained unclear.
Therefore, researchers sought to evaluate whether early noninvasive ventilation improved survival in these patients.
For the multicenter trial, researchers enrolled 374 critically ill immunocompromised patients at 28 ICUs in France and Belgium.
Of those, nearly 85% were receiving treatment for hematologic malignancies and solid tumors. Participants were randomly assigned to receive early noninvasive ventilation or oxygen therapy alone.
Results showed that at 28 days after randomization, 46 deaths had occurred in the noninvasive ventilation group compared with 50 in the oxygen group (P=0.47). In addition, oxygenation failure occurred in 73 patients and 82 patients, respectively (P=0.20).
Researchers found no significant differences in ICU-acquired infections, duration of mechanical ventilation, or lengths of ICU or hospital stays between the two treatment arms.
The authors note that the study power was limited and this may affect the applicability of the findings.
Early noninvasive ventilation did not reduce 28-day mortality compared with oxygen therapy alone.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|